Open AccessMyasthenia Gravis: Analytical Methods for the Determination in Biological Fluids of First-Line Therapeutic Agents Used in the Management of the Disease
Author(s) -
Chika J Mbah
Publication year - 2019
Publication title -
journal of pharmacology, pharmaceutics, and pharmacovigilance
Language(s) - English
Resource type - Journals
ISSN - 2639-5649
DOI - 10.24966/ppp-5649/100010
Subject(s) - myasthenia gravis , acetylcholine receptor , neuromuscular junction , medicine , antibody , muscle weakness , autoimmune disease , nicotinic acetylcholine receptor , disease , immunology , chemistry , neuroscience , receptor , biology
Myasthenia Gravis (MG) an autoimmune disease is the prototype of neuromuscular junction disease caused by auto antibodies against the nicotinic Acetylcholine Receptor (AChR) located in the postsynaptic muscle endplate membrane [1,2]. The autoimmune disorder is characterized by weakness and fatigability of the voluntary muscle arising from the distortion and simplification of the postynaptic muscle membrane and consequent attachment of antibodies and complement to the membrane.